Molecule Details
| InChIKey | OURRXQUGYQRVML-AREMUKBSSA-N |
|---|---|
| Canonical SMILES | Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.97 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB13931 |
|---|---|
| Drug Name | Netarsudil |
| CAS Number | 1254032-66-0 |
| Groups | approved investigational |
| ATC Codes | S01EE51 S01EX05 |
| Description | A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with o... |
Categories: Acids, Carbocyclic Alanine Amino Acids Amino Acids, Peptides, and Proteins Antiglaucoma Preparations and Miotics Benzene Derivatives Ophthalmologicals Prostaglandins, Synthetic Rho Kinase Inhibitor Rho Kinase Inhibitors Sensory Organs
Cross-references: BindingDB: 50546247 CHEMBL4594250 ChemSpider: 34980598 RxCUI: 1992864 Wikipedia: Netarsudil ZINC: ZINC000113149554